Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
Kestra Medical Technologies, Ltd. has a planned sale of common stock reported on Form 144. The filing covers 3,980 shares of common stock to be sold through Merrill Lynch, with an indicated value of $90,560.62 and a date of July 30, 2026 on NASDAQ.
The securities to be sold arose from the vesting of performance share unit awards on July 17, 2026, which were granted as part of the issuer’s equity compensation plan.
Kestra Medical Technologies, Ltd. will hold its 2026 Annual General Meeting on September 9, 2026 at 9:00 a.m. Eastern Time, conducted as a virtual-only webcast at www.virtualshareholdermeeting.com/KMTS2026. Shareholders of record at the close of business on July 17, 2026 may attend and vote.
Shareholders are asked to elect three Class II directors (Traci S. Umberger, Raymond W. Cohen, and Kevin Reilly) to terms ending in 2029 and to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending April 30, 2027. The proxy materials outline a classified eight‑member board, committee structures, related‑party transactions, and detailed 2026 executive pay, including $7,501,904 in total compensation for CEO Brian Webster. Kestra is an emerging growth company, so no advisory vote on executive compensation is included.
Kestra Medical Technologies, Ltd. executive Timothy P. Moran, Chief Business Officer, reported an acquisition of 39,113 common shares. These shares were earned from a July 17, 2025 grant of performance-based RSUs ("PSUs") that vested 100% on July 15, 2026 after specified performance goals were achieved. The PSUs settled at a reported price of $0.0000 per share, increasing Moran’s direct holdings to 81,601 common shares. The transaction was coded as a grant/award acquisition, not a market purchase or sale, and was not indicated as being under a Rule 10b5-1 trading plan.
Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share. The shares were earned from performance-based RSUs granted July 17, 2025, which vested 100%, bringing his direct holdings to 133,471 shares.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem acquired 44,118 Common Shares on July 15, 2026, at 0.0000 per share, upon vesting of performance-based RSUs granted on July 17, 2025 after achievement of specified goals. Following this award, he directly owns 112,079 Common Shares.
Kestra Medical Technologies, Ltd. reported that director and General Counsel Traci S. Umberger acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share, reflecting the vesting of performance-based RSUs (PSUs) granted on July 17, 2025. After this award, Umberger directly holds 221,634 Common Shares.
Kestra Medical Technologies President and CEO Brian Daniel Webster reported several Common Share transactions dated July 15, 2026. He acquired 176,470 shares at $0.0000 per share upon full vesting of performance-based RSUs granted in 2025, then sold a total of 15,000 shares at weighted-average prices of $22.0105, $22.6333 and $23.9983, with underlying trade prices ranging from $21.45 to $24.10, under a Rule 10b5-1 trading plan adopted September 29, 2025. Following these transactions, he directly owned 556,937 Common Shares.
A notice by Brian Webster covers 15,000 shares of Kestra Medical Technologies, Ltd. common stock for potential sale, with a value of 336,609.41. Merrill Lynch, 225 Liberty St Floor 37, New York, NY 10281, and Nasdaq are listed in connection with this transaction. The shares were acquired on 01/01/2026 via a restricted share issuance granted as part of the issuer’s equity compensation plan.
The disclosure also lists three prior sales of 15,000 common shares each on 04/15/2026, 05/15/2026 and 06/15/2026, with reported values of 300,671.04, 314,329.85 and 312,142.94, respectively.
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital health company focused on cardiac recovery. Its Cardiac Recovery System platform is anchored by the ASSURE wearable cardioverter defibrillator, which has protected nearly 40,000 patients as of April 30, 2026.
The ASSURE system emphasizes patient comfort and compliance via SensorFit garments and high-fidelity ECG, achieving median wear of more than 23 hours per day. In the 21,612‑patient ACE-PAS study, ASSURE showed a 100% conversion rate for VT/VF events and low false alarms, with a software update targeting further reductions.
Kestra estimates a WCD addressable market of about $10 billion in the U.S. and $14 billion internationally, versus 2025 global WCD revenues of $1.1 billion and only 16% penetration of eligible U.S. patients. Revenue comes primarily from leasing ASSURE as Durable Medical Equipment, supported by Medicare and contracts covering over 290 million U.S. lives. Key risks include a history of net losses, dependence on ASSURE WCD, reliance on limited suppliers, extensive healthcare and fraud‑and‑abuse regulation, identified material weaknesses in internal control over financial reporting, and significant influence from Bain Capital.